The kidney cancer prognostic analysis system, on the other hand, has good operability to classify risk and predict survival, and also helps in clinical trial design and development of follow-up strategies. The development of prognostic analysis systems using molecular markers is a trend in the prognostic analysis of kidney cancer. I. UISS Researchers at the University of California, Los Angeles UCLA have developed a kidney cancer risk grading system, the UISS (University of California, Los Angeles Integrated Staging System). The UISS classifies kidney cancer into five groups based on TNM stage (1997), tumor pathology grade (Furhman Grade) and ECOG quality of life score, and the difference in prognosis among these five groups is significant. The UICC (UCLA Integrated Staging System) staging system was used to stratify these patients into three different risk groups i.e. low risk, intermediate risk and high risk. For limited tumors, the 5-year survival rate was 92% for the low-risk group; 67% for the intermediate-risk group; and only 44% for the high-risk group. UISS has been shown to be an accurate predictor of survival in non-metastatic kidney cancer, but its predictive accuracy for metastatic kidney cancer is poor. It can only differentiate different patients into low, intermediate and high risk groups. Therefore, compared to other systems, UISS provides less information to guide treatment. SSIGN In 2002, the Mayo Clinic reviewed and analyzed more than 1,800 kidney cancer cases and developed a scoring system (SSIGN) for tumor staging, tumor size, tumor pathology grading, and tumor necrosis. Based on the SSIGN score, the likelihood of patient survival from 1 to 10 years can be estimated. III.Nomogram In 2001, Memorial Sloan-Kettering Cancer Center MSKCC retrospectively analyzed 601 postoperative renal cancer patients and developed the POSTOPERATIVE PROGNOSTIC (POSTOPERATIVE PROGNOSTIC) based on it to evaluate postoperative renal cancer. NOMOGRAM FOR RENAL CELL CARCINOMA). The graph was used to predict the likelihood of five-year tumor-free survival in newly diagnosed kidney cancer patients; in 2005 Memorial Sloan-Kettering Cancer Center (MSKCC) further increased the number of patients to 833 and developed the NOMOGRAM FOR RECURRENCE OF CLEAR CELL RENAL CELL CARCINOMA). The graph was used to predict the likelihood of five-year tumor-free survival in patients with renal clear cell carcinoma. The combination of NOMOGRAM as a basis and NOMOGRAM software can make the prognostic analysis more accurate and efficient.